HOME PAGE  SEARCH

Landmark Alzheimer's Drug Cleared for Clinical Trials

Researchers have developed a number of new drugs in recent years to treat Alzheimer's disease, but they must undergo years of testing before they ever make it to market. That process has begun with one promising new drug -- Bryostatin -- which has received approval from the Food and Drug Administration to begin clinical trials.

The drug showed pre-trial promise for not only treating Alzheimer's symptoms and reverse memory loss, but also address its underlying causes.

 

"We are very excited about the FDA's agreement for Blanchette Rockefeller Neurosciences Institute (BRNI) to move forward with clinical trials," said Dr. Daniel Alkon, scientific director of the institute. "Bryostatin shows the promise to repair and protect against neuron-degeneration caused by Alzheimer's disease, stroke and other brain trauma, as well as enhance the brain's normal memory functions.

 

Bryostatin became an Alzheimer's drug by accident. It was originally created as an anti-cancer chemotherapy. When BRNI scientists extensively tested PKC activators against Alzheimer's disease models, they discovered the drug's hidden potential to stop Alzheimer's disease, the company said.

 

In preclinical testing, BRNI scientists experimented with Bryostatin on three species of Alzheimer's disease transgenic mice, each species based on different human Alzheimer's disease genes. The company says the test results revealed that Bryostatin, and a related class of drugs discovered at BRNI, can reduce the toxic Alzheimer's disease protein A Beta, restore lost synapses, and protect against the loss of memory functions. In related preclinical testing, Bryostatin has been shown to enhance and restore memory by rewiring connections in the brain previously destroyed by stroke, head trauma, or aging itself.

 

The Phase II clinical trials, slated to begin in approximately two to four months, will test these preclinical findings on human Alzheimer's disease patients as well as controls, along with Bryostatin's effects on molecular targets in the human body, such as the signaling enzyme PKC.

 

The drug's side effects will also be carefully monitored using low doses that were previously found to be generally benign in human cancer patients.

 

"With the potential to not just treat symptoms, but also stop the causes, the Bryostatin trial on Alzheimer's disease patients represents a new direction for the treatment of a disease with no current cure," said Alkon. "And the timing is crucial because as many as 5.3 million people live with Alzheimer's disease in the United States alone, with a new American developing Alzheimer's disease every 70 seconds."

 

(Article courtesy of ConsumerAffairs.com)

Email or share this story

Alzheimer's Drug May Aid Stroke Survivors with Dementia -- 5/10/04

Alzheimer's Care Costs Skyrocket; Impact of Disease Spreads -- 3/31/09

Don't Confuse Confusion for Dementia -- 12/27/04

Alzheimer's and HIV-Related Memory Loss Linked by Protein -- 12/15/09

Improper Sedative Use Kills Alzheimer's Patients Early -- 4/3/07

_____

View The Caregiver's Hotline in which this article first appeared

Back to Top